Clinical and economic analysis of biologic drugs in treatment of psoriasis
Purpose. To evaluate the cost effectiveness of use of ustekinumab (Stelara®), infliximab (Remicade®) and adalimumab (Humira®) for treatment of moderate and severe psoriasis. Methods. A cost-effectiveness analysis and budget impact analysis have been conducted. Clinical efficacy was evaluated by redu...
Main Authors: | A. A. Kubanov, S. K. Zyryanov, D. Yu. Belousov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2018-05-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/25 |
Similar Items
-
Personalization of an anti-cytokine therapy of psoriatic patients
by: A. A. Kubanov, et al.
Published: (2017-08-01) -
Pharmacoeconomic analysis of Actemra<sup>®</sup> in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy
by: S. K. Zyryanov, et al.
Published: (2018-05-01) -
Экономическая эффективность применения гефитиниба в качестве терапии 1-й линии у пациентов с распространённым немелкоклеточным раком лёгкого при наличии мутации в гене EGFR
Published: (2018-06-01) -
Фармакоэкономический анализ применения бортезомиба для подкожного введения у пациентов с рецидивирующей множественной миеломой
Published: (2018-06-01) -
Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson’s disease
by: D. Yu. Belousov, et al.
Published: (2018-05-01)